U.S. specialty drugmaker Allergan Inc said late on Tuesday it will buy MAP Pharmaceuticals Inc for about $958 million in cash.
As per the deal, Allergan will acquire 100 percent of the shares of MAP Pharmaceuticals for a price of $25 per share, a 60 percent premium over MAP's closing stock price on the Nasdaq of $15.58 on Tuesday.
Join the Conversation